AFP and acute myeloid leukemia: The median OS superimposable between patients who did and did not develop IFDs (225 days vs. 325 days);Failure to obtain CR/CRi (IFD incidence: 22% vs. 6%) and VEN–HMA treatment for r/r AML, compared to newly diagnosed (IFD incidence: 19% vs. 5%);No significant differences in IFD’s incidence or mortality between the different AFP strategies;AZA associated with a higher risk of IFD (low sample size).